相关实验视频

Updated: May 5, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

准NAT10 通过ac4C介导的SMAD3 mRNA稳定性抑制肝癌发生

Yigan Zhang¹, Yanbin Dong², Shuwen Chen¹

¹Institute of Biomedical Research Department of Infectious Diseases Regulatory Mechanism and Targeted Therapy for Liver Cancer, Shiyan Key Laboratory Hubei Provincial Clinical Research Center for Precise Diagnosis and Treatment of Liver Cancer Taihe Hospital (First Clinical College of Medicine) Hubei University of Medicine Shiyan Hubei China.

Exploration (Beijing, China)

|January 1, 2026

概括

N-乙转移酶10 (NAT10) 通过稳定SMAD3mRNA,促进肝细胞癌 (HCC). 一种新的抑制剂NAT10-2023有效地阻断了NAT10,为HCC治疗提供了潜在的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生化学

背景情况:

肝细胞癌 (HCC) 具有显著的发病率和死亡率,有效的治疗方法很少.
N-乙转移酶10 (NAT10) 是mRNA ac4C修饰中的关键酶,也是HCC进展的生物标志物.
在肝癌发生和向抑制剂中NAT10的精确作用需要进一步研究.

研究的目的:

阐明NAT10在肝癌发生中的关键作用.
为了确定针对NAT10的小分子抑制剂,用于HCC治疗.
研究NAT10促进HCC进展的机制.

主要方法:

对HCC组织中NAT10表达的分析和与预后的相关性.
在体外和体外功能研究涉及NAT10下调.
关于NAT10介导的mRNA稳定和信号通路激活的机制研究.
鉴定和评估一种新型小分子抑制剂,NAT10-2023.

主要成果:

在HCC组织中高NAT10表达与预后不佳有关.
NAT10的下调抑制HCC细胞的增殖,入侵,EMT,并在体外促进阿诺基斯.
在体内,NAT10的枯竭会影响瘤生长,转移和肝癌发生.
NAT10通过ac4C修饰稳定SMAD3mRNA,激活TGF-β通路.
NAT10-2023有效抑制NAT10活动,减少RNAac4C修饰,并抑制瘤的进展.

结论:

通过ac4C修饰,NAT10通过调节SMAD3mRNA稳定性来驱动HCC的进展.
抑制NAT10代表了对HCC的有前途的治疗策略.
NAT10-2023证明了作为针对癌症治疗中NAT10的新型治疗候选者的潜力.

关键词:

在RNA ac4C修改过程中.肝癌肝癌是一种肝癌.有针对性的药物开发.

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

相关概念视频

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...